
Prolaris®

Prostate Cancer Prognostic Test

Patient guide to the Prolaris® test on prostate cancer





A common diagnosis

Prostate cancer is recognized as one of the most important medical problems facing men. More than 1.4 million men were diagnosed with prostate cancer worldwide in 2020. About 1 in 8 men receive a diagnosis of prostate cancer in their lifetime.

However, most prostate cancers are slow growing, and most patients are diagnosed at an early stage with very good survival rates. Unfortunately, a portion of men will have an aggressive type of prostate cancer and have a significant risk that the prostate cancer will spread.

Therefore, it is important to assess the aggressiveness of the tumor as accurately as possible to determine the most appropriate treatment strategy.

Confused about which prostate cancer treatment is right for you?



A diagnosis of prostate cancer can make you feel like your world is collapsing and deciding what to do next can be overwhelming and confusing.

Myriad Genetics' Prolaris Prostate Cancer Prognostic Test, provides personalized genomic information about how your prostate cancer is behaving, giving you and your physician confidence to choose the treatment plan that is right for you.

How Prolaris® benefits you

Prolaris provides new information about your cancer that no other test can.

The Prolaris test can determine just how unique and aggressive your prostate cancer truly is.

Your Prolaris Score provides individualized information about your specific cancer to help you and your physician develop the appropriate treatment plan.



Prolaris provides answers to your most pressing questions




- What is the risk of my cancer spreading outside of the prostate?
- What is my risk to die from my prostate cancer?
- · How should my cancer be treated
- Am I a candidate for active surveillance?
- Should I consider active treatment?


What is Prolaris®?

Prolaris is a gene expression test that can help your doctor predict the course of your disease.

Prolaris accurately measures the activity of specific genes that influence tumor growth and allows clear conclusions about tumor prognosis. Low gene activity is associated with a lower risk of tumor progression. High activity is associated with a higher risk.^{3,4}



This information is paired with other diagnostic tools like PSA and Gleason grading to result in your individual risk.



Prolaris® is personalizing prostate cancer treatment

The Prolaris test results come with a patient-friendly summary page designed to help you clearly and confidently understand which treatment pathway might be right for you.^{5,6}

Lower Prolaris Score Higher Prolaris Score

Active surveillance

Men safe for active surveillance

Active surveillance means monitoring the cancer closely. Usually this includes a doctor visit with a prostate-specific antigen (PSA) blood test about every 6 months and a digital rectal exam (DRE) at least once a year. Prostate biopsies and imaging tests may be done every 1 to 3 years as well.

Single-modal treatment

- Men not safe for active surveillance
- Candidate for single-modal therapy

Single-modal treatment refers to a situation in which only one local treatment modality is chosen from several options available. For example surgery or radiation.

Multi-modal treatment

- Men not safe for single-modal therapy
- Candidate for multi-modal therapy

Multi-modal treatment is a combination of several treatment options. Multi-modal therapy is tailored to each patient's unique case. For example surgery and radiation therapy or radiation therapy plus hormone therapy.



How Prolaris® works

Talking to your healthcare provider about the Prolaris® biopsy test



Better answers start with you

Prolaris is best performed on your initial biopsy and before you've made a treatment decision. To get started, first talk to your urologist to see if prognostic testing of your tumor might be appropriate.



Doctor orders the Prolaris biopsy test

The test can be requested from one of the performing pathologies in your country or from Myriad Genetics' central laboratoty in Salt Lake City, USA. The pathologist requires a sample from your existing prostate biopsy. No additional blood or biopsy samples are required.



Your genes are analyzed in the pathology lab

Using the latest
e gene expression
technology based on
tumor RNA, Prolaris
measures how quickly
or aggressively your
cancer is growing.

rom
te



Test results available in around 2 weeks

Once the results are available, they are sent to your doctor's office. Your doctor will then help you understand how your cancer is behaving, giving you confidence to take the next step.



Be prepared

Do your research on possible prostate cancer treatments, side-effects, and biomarker tests - like Prolaris. Come prepared to your oncologic consultation with any information the doctor or staff may need to see. Make sure to bring along the Prolaris patient guide.



Be open and confident

Remember that your doctor is on your side. You both want what's best for you and helping successfully manage your cancer is everyone's top priority. So just be open and honest about potential treatments or possible side-effects.



Bring your support team

The support of family members or close friends can help facilitate the conversation with your doctor and help act as a co-advocate for your care at your next appointment.

Myriad Genetics advantage

- 5 million patients tested
- Prolaris is recommended by national cancer organizations and treatment guidelines⁸
- Committed to making testing easy and affordable to all

References:

- 1. International Agency for Research on Cancer, WHO, GLOBOCAN 2022
- 2. American Cancer Society, Facts & Figures 2022
- 3. Cuzick, J. et al. British Journal of Cancer 2012
- 4. Cuzick, J. et al. British Journal of Cancer 2015
- 5. Lin, D.W. et al. Urologic Oncology: Seminars and Original Investigations. 2018
- 6. Tward, J.D. et al. Journal of Clinical Oncology. 2020
- 7. Tward, J.D. et al. International Journal of Radiation Oncology, Biology, Physics. 2021
- 8. NCCN 2022, ASCO 2019, EAU 2022



Myriad Genetics GmbH / Leutschenbachstrasse 95, 8050 Zurich, Switzerland / Myriad Genetics, the Myriad Genetics logo, Prolaris and the Prolaris logo are either trademarks or registered trademarks of Myriad Genetics, Inc., in the United States and other jurisdictions. ©2022, Myriad Genetics GmbH. Not for distribution in USA.

www.myriadgenetics.eu / info@myriadgenetics.eu

PROL_PATIENT_BRO_EN_04_22

For more information visit www.myriadgenetics.eu